Browsing Tag

PRNewswire

54058 posts
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ — GenFleet Therapeutics, a clinical-stage…
Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting

Immunofoco Biotech to Unveil Solid Tumor CAR-T Programs Clinical Trial Data at 2024 ASCO Meeting

CHICAGO, June 2, 2024 /PRNewswire/ — On June 1st, 2024, Immunofoco Biotech,…
Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling!

Z Grills Announces Unprecedented "Buy 1, Get 10 Grills" Promotion, Unlocking a Lifetime of Easier Grilling!

ONTARIO, Calif., June 1, 2024 /PRNewswire/ — Mark your calendars, grill masters!…
ICECO Launches APL35 on Indiegogo – The World's Lightest Aluminum Dual-Zone Freezer

ICECO Launches APL35 on Indiegogo – The World's Lightest Aluminum Dual-Zone Freezer

BREA, Calif., June 1, 2024 /PRNewswire/ — ICECO, a leading expert in…
Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple

Tag along with Jason in Zhengzhou: Experiencing Kung Fu at the Shaolin Temple

BEIJING, May 30, 2024 /PRNewswire/ — This is a report from China.org.cn about…
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting

TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024 Annual Meeting

Poster presentation features the interim data from an ongoing Phase 1b clinical…
Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse

Immunocan Launches Innovative Alpaca-derived Nanobody Discovery Platform: ImmuAlpaca® Mouse

BOSTON, June 1, 2024 /PRNewswire/ — Immunocan announces significant progress in the…
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy

Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically…